Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development

Melanie Janning; Walter Fiedler

doi:10.2217/fon.14.53

Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development

Standard

Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. / Janning, Melanie ; Fiedler, Walter.

in: FUTURE ONCOL, Jahrgang 10, Nr. 7, 01.05.2014, S. 1157-65.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Janning, M & Fiedler, W 2014, 'Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development', FUTURE ONCOL, Jg. 10, Nr. 7, S. 1157-65. https://doi.org/10.2217/fon.14.53

APA

Janning, M., & Fiedler, W. (2014). Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. FUTURE ONCOL, 10(7), 1157-65. https://doi.org/10.2217/fon.14.53

Vancouver

Janning M , Fiedler W. Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. FUTURE ONCOL. 2014 Mai 1;10(7):1157-65. https://doi.org/10.2217/fon.14.53

Bibtex

@article{8d410d6f67324b9d92594fd29e98d825,

title = "Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development",

abstract = "Volasertib is a potent inhibitor of Polo-like kinase (PLK) 1 and to lesser extent also PLK2 and PLK3. PLKs are key regulators of the cell cycle and volasertib blocks cells in G2-M phase of the cell cycle. The compound has been evaluated in Phase I and II studies in acute myeloid leukemia and solid tumors. Side effects are mainly hematological. In acute myeloid leukemia (AML), a randomized Phase II study has been conducted in elderly patients unfit for intensive chemotherapy. Patients have been randomized to a combination of volarsetib and low-dose cytarabine versus low-dose cytarabine alone. Preliminary results show significantly higher rates of complete remission and of complete remission with incomplete hematological recovery in the combination versus the monotherapy arm, with 31% and 13%, respectively. Longer event-free survival was observed with the combination with 5.6 versus 2.3 months, respectively (p = 0.0237). These encouraging data supported the initiation of an international Phase III trial, which currently underway, to confirm these results. Volasertib has not yet been approved for regular clinical use.",

author = "Melanie Janning and Walter Fiedler",

year = "2014",

month = may,

day = "1",

doi = "10.2217/fon.14.53",

language = "English",

volume = "10",

pages = "1157--65",

journal = "FUTURE ONCOL",

issn = "1479-6694",

publisher = "Future Medicine Ltd",

number = "7",

}

RIS

TY - JOUR

T1 - Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development

AU - Janning, Melanie

AU - Fiedler, Walter

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Volasertib is a potent inhibitor of Polo-like kinase (PLK) 1 and to lesser extent also PLK2 and PLK3. PLKs are key regulators of the cell cycle and volasertib blocks cells in G2-M phase of the cell cycle. The compound has been evaluated in Phase I and II studies in acute myeloid leukemia and solid tumors. Side effects are mainly hematological. In acute myeloid leukemia (AML), a randomized Phase II study has been conducted in elderly patients unfit for intensive chemotherapy. Patients have been randomized to a combination of volarsetib and low-dose cytarabine versus low-dose cytarabine alone. Preliminary results show significantly higher rates of complete remission and of complete remission with incomplete hematological recovery in the combination versus the monotherapy arm, with 31% and 13%, respectively. Longer event-free survival was observed with the combination with 5.6 versus 2.3 months, respectively (p = 0.0237). These encouraging data supported the initiation of an international Phase III trial, which currently underway, to confirm these results. Volasertib has not yet been approved for regular clinical use.

AB - Volasertib is a potent inhibitor of Polo-like kinase (PLK) 1 and to lesser extent also PLK2 and PLK3. PLKs are key regulators of the cell cycle and volasertib blocks cells in G2-M phase of the cell cycle. The compound has been evaluated in Phase I and II studies in acute myeloid leukemia and solid tumors. Side effects are mainly hematological. In acute myeloid leukemia (AML), a randomized Phase II study has been conducted in elderly patients unfit for intensive chemotherapy. Patients have been randomized to a combination of volarsetib and low-dose cytarabine versus low-dose cytarabine alone. Preliminary results show significantly higher rates of complete remission and of complete remission with incomplete hematological recovery in the combination versus the monotherapy arm, with 31% and 13%, respectively. Longer event-free survival was observed with the combination with 5.6 versus 2.3 months, respectively (p = 0.0237). These encouraging data supported the initiation of an international Phase III trial, which currently underway, to confirm these results. Volasertib has not yet been approved for regular clinical use.

U2 - 10.2217/fon.14.53

DO - 10.2217/fon.14.53

M3 - SCORING: Journal article

C2 - 24947257

VL - 10

SP - 1157

EP - 1165

JO - FUTURE ONCOL

JF - FUTURE ONCOL

SN - 1479-6694

IS - 7

ER -